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HIV-1 gp41 envelope IgA is frequently elicited after
transmission but has an initial short response half-life
NL Yates1,2, AR Stacey3, TL Nolen4, NA Vandergrift1,2, MA Moody1,5, DC Montefiori1,6, KJ Weinhold1,6,7,
WA Blattner8, P Borrow3, R Shattock9, MS Cohen10, BF Haynes1,2,7 and GD Tomaras1,6,7,11
Prevention of HIV-1 transmission at mucosal surfaces will likely require durable pre-existing mucosal anti-HIV-1
antibodies (Abs). Defining the ontogeny, specificities and potentially protective nature of the initial mucosal virus-
specific B-cell response will be critical for understanding how to induce protective Ab responses by vaccination. Genital
fluids from patients within the earliest stages of acute HIV-1 infection (Fiebig I–VI) were examined for multiple anti-HIV
specificities. Gp41 (but not gp120) Env immunoglobulin (Ig)A Abs were frequently elicited in both plasma and mucosal
fluids within the first weeks of transmission. However, shortly after induction, these initial mucosal gp41 Env IgA Abs
rapidly declined with a t1/2 of B2.7 days. B-cell-activating factor belonging to the TNF family (BAFF) was elevated
immediately preceding the appearance of gp41 Abs, likely contributing to an initial T-independent Ab response.
HIV-1 transmission frequently elicits mucosal HIV-1 envelope-specific IgA responses targeted to gp41 that have a short
half-life.
INTRODUCTION
Immunoglobulin (Ig)A antibodies (Abs) are a first line of
immune protection for many viral infections at mucosal
surfaces. The mechanisms by which mucosal IgA is induced
and how innate immune recognition of pathogenic micro-
organisms have a role in Ig class switch recombination are an
area of intensive study that ultimately will inform HIV-1
vaccine design1. There is a resurgence of interest in the potential
role of pre-existing mucosal IgA Abs in protection against HIV-1.
Recent studies in non-human primates indicate that Abs to
gp41 (ref. 2) and in particular IgA Abs to gp41 (ref. 3), if pre-
existing, may have important functional roles in protection
from infection. In acute HIV-1 infection (AHI), humoral
responses arise too late to be effective in the control of HIV-1
replication,4 and there is significant impairment of the B-cell
response (reviewed in refs 5 and 6). HIV-1 transmission results
in rapid turnover of CD4þ T lymphocytes7 and specific
depletion of CCR5þ CD4þ T cells in the gut.8–10 Moreover,
HIV-specific CD4þ T cells are preferentially infected and lost
during infection.11,12 Thus, T cell help for maturation of the
B-cell response is likely limited during the early stages of HIV-1
infection. HIV-1 also specifically causes deficiencies in B-cell
function,13–15 and viral cofactors such as the viral envelope
glycoprotein gp120 (refs 16 and 17) and Nef18,19 have been
proposed to mediate B-cell dysfunction in HIV-1 infection. A
cytokine storm early in AHI20 may also account for some
aspects of B-cell dysfunction.
There is a narrow window of vulnerability after virus
exposure that could allow Abs with antiviral function to inhibit
HIV-1 at mucosal surfaces.21,22 Pre-existing HIV-1-specific
mucosal Abs present at the time of transmission could block
HIV-1 acquisition. The mechanisms by which Abs can inhibit
HIV-1 movement across the mucosal barrier include direct
virus neutralization, viral aggregation, inhibition of transcy-
tosis, intra-epithelial neutralization, phagocytosis, inhibition
through mucus, and Fc receptor-mediated neutralization (Ab-
dependent cellular cytotoxicity) (reviewed in refs 23 and 24).
Analyses of the initial mucosal Ab responses to HIV-1 infection
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will enable a more complete understanding of the effects of
HIV-1 on the B-cell arm of the immune response. Moreover,
mucosal Abs that are easily elicited by HIV-1 and target the
HIV-1 Env may be a potential target for vaccine design if
the durability of the response can be improved. Antibodies that
are easy to elicit and do not require the same extensive level of
somatic hypermutation thought to be required for broadly
neutralizing Abs24 would, if protective, be ideal as targets for
HIV-1 vaccine immunogen design. Thus, understanding the
properties of the initial IgA response in the mucosa following
HIV-1 transmission should enable a better understanding of
how to best elicit durable humoral immunity for preventing
HIV-1 acquisition and/or virus replication.
Here we report that IgA Abs to gp41 Env arise initially in
acute infection and are frequently detected in genital fluids.
Mucosal IgA Abs to gp120 Env and to other parts of HIV-1 arise
later during acute infection. Moreover, we examined potential
regulators of the initial Ab response and found that B-cell-
activating factor belonging to the TNF family (B-cell-activating
factor (BAFF)) was elevated preceding the spike in anti-HIV-1
Abs. This early BAFF elevation coupled with the lack of a robust
and sustained mucosal HIV-1-specific IgA response is con-
sistent with an initial HIV-1-specific Ab response that is T
independent. Thus, the initial mucosal Env Ab response is
limited in specificity to gp41 during the early stages of infection
and has a short half-life.
RESULTS
Frequency, specificity and timing of anti-HIV-1 mucosal
Abs during AHI
To determine if mucosal Abs to the HIV-1 envelope arise within
the first few months of AHI and whether mucosal Abs to other
regions of HIV-1 are elicited during AHI, we examined the
frequency of detection of IgA and IgG responses to the HIV-1
envelope proteins, gp41 and gp120 (Figure 1a and c); and to
HIV-1 antigens Gag, Tat, Nef, Integrase (p31), and reverse
transcriptase (RT) (Figure 1b and d) in up to 30 patients
(N¼ 170 samples) for plasma and up to 23 patients (N¼ 119
samples) for mucosal samples (Supplementary Table S1
online). HIV-1 gp41-specific IgA was detected in the genital
secretions of 20/23 (87%) acutely infected individuals and
plasma gp41-specific IgA was present in 29/30 (97%) of AHI
patients, all of whom were positive for HIV-1 gp41 IgG in both
plasma and genital secretions. Plasma HIV-1 gp41-specific IgM
was frequently detected in 25/28 (89%) patients; however, only
about half of acute patients had detectable mucosal gp41-
specific IgM (11/21, 52%). Additionally, the vast majority of
patients had gp41 IgG and IgA Abs that were specific for the
immunodominant epitope (Figure 1c); whereas, there were no
detectable membrane proximal external region (MPER)
epitope-specific responses above 1 ng/ml of mucosal fluid.
Anti-gp120 IgA Abs were detected at later stages of acute
infection in plasma and mucosal samples and they were less
frequently detected than gp41 Env-specific Abs. Mucosal gp120
IgA was present in 27% of AHI patients, and mucosal gp120
IgG was present in 40% of AHI patients.
To determine whether other HIV-1 proteins, in addition to
the HIV-1 Env, stimulated a humoral response in acute
infection, we assessed Ab responses to Gag, p66 RT, p31
Integrase, Tat, and Nef. The majority of patients developed
systemic and mucosal IgG and IgA responses to Gag and p66
RT, whereas IgG and IgA Ab responses to p31 Integrase, Tat,
and Nef were less commonly detected by B133 days post
enrollment (Figure 1b and d).
To evaluate the timing of the appearance of HIV-specific IgA
during AHI, we determined the frequency of plasma (Table 1a)
and mucosal (Table 1b) IgA specificities by Fiebig stage.25 We
evaluated plasma samples from 30 Center for HIV/AIDS
Vaccine Immunology (CHAVI) 001 subjects (most were
enrolled during stage 3 or later) and 25 plasma donors (Fiebig
stages I/II onward until sample collection stopped). In plasma,
gp41 IgA and Gag IgA were present in 26.1% and 8.7% of
subjects during Fiebig stages I/II, respectively. RT- and Nef-
specific IgA were not detected in samples obtained during
Fiebig stages I/II and were more commonly detected in samples
from stages IV–VI. HIV gp120- and p31-specific IgA were less
frequent even at later stages V/VI. In mucosal samples from 23
CHAVI 001 subjects, we observed that gp41, Gag-, and gp120-
specific IgA were first detected during Fiebig stage IV and were
more frequently detected during Fiebig stages V/VI. RT-, Nef-,
and p31-specific IgA were only detected in samples obtained
during Fiebig stages V/VI. In the HIV-1 seroconversion plasma
donor cohort, we also examined the time since T0 (plasma viral
RNA¼ 100 copies/ml)4,20,26 for the appearance of IgA Abs.
During Fiebig stages I–VI, in those plasma donors with
detectable HIV-1-specific plasma IgA, the median time to
appearance of gp41-specific IgA was 13.5 days post T0 (range of
9–18 days), whereas the median time for the appearance of
Gag-specific IgA was 25.5 days post T0 (range of 14–40 days)
(Table 1c). Gp120 IgA Ab responses were not detected in these
samples due to the early Fiebig staging in this cohort, consistent
with the lack of early IgG gp120 responses we previously
reported.4 Taken together, these data show that HIV-specific
IgA is frequently present in the genital tract, as well as, present
systemically during AHI. The initial Ab specificities include
predominantly the immunodominant epitope in gp41, whereas
Abs to gp120 and other HIV-1 proteins appear later in some
individuals.
HIV-1-specific mucosal Ab concentrations
To examine the concentrations of HIV-1-specific IgA
responses in both plasma and mucosal samples following
HIV-1 transmission, we evaluated HIV-1-specific Ab responses
in the CHAVI 001 AHI cohort that were enrolled during AHI
and followed for up to 133 days after enrollment.6,27 Mucosal
Ab concentrations were measured in 64 samples from 12
patients (seminal plasma from nine males and cervicovaginal
lavage from three females) to quantify HIV-1-specific Ab
concentrations relative to total (non-specific) Ab concentra-
tions. During AHI, HIV-1-specific IgG and IgA were both
frequently detected in systemic and mucosal compartments,
and the observed peak concentrations of anti-gp41 Abs (IgG,
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IgA, and IgM) (Table 2) were measured during Fiebig stage III
through V/VI. On an average, there were over two logs more
HIV-1 gp41-specific IgG in the plasma compared with IgA at
the peak of the response during AHI. This was partly reflective
of the difference in the total non-HIV-specific levels of IgG/IgA
that is present in plasma (mean 43.8 mg/ml of IgG vs. 4.9±mg/ml
IgA, an 8.9-fold difference). In the genital secretions,
gp41-specific IgG was on an average 11-fold higher than
gp41-specific IgA (Table 2). However, total IgG and IgA levels
within the mucosal samples that we examined were more
similar to one another (168±STDEV 209.5 mg/ml of total IgG
vs. 133.2±STDEV 278.2 mg/ml of total IgA); consistent with
normal Ab ranges28 and consistent with previous reports that
demonstrated that, unlike intestinal fluid containing high levels
of SIgA, semen and cervicovaginal fluid contain more IgG than
IgA.29 As expected, in mucosal secretions total IgM levels were
lower than total IgG and IgA. In those samples with HIV-1-
specific IgM, the specific activity levels are higher than the IgG
and IgA measurements, in part, due to the lower concentrations
of total IgM (mean 10.2 mg/ml±STDEV 11.7 mg/ml) that were
present. In addition, there were no significant differences in
total or gp41-specific IgG and IgA in plasma or genital fluid
collections between males and females from this study
(Supplementary Figure S1 online). Taken together, the levels
of HIV-1 Env-specific IgA in genital fluids during acute
infection were low compared with HIV-1 Env-specific IgG.
Differences in systemic and mucosal IgA and IgG
concentrations and specificities
To examine whether the HIV-1-specific mucosal Ab response
was likely derived locally or transudated from plasma, we
compared the levels of HIV-specific Abs in plasma and genital
tract compartments across all time points within the first 133
days post enrollment. We first compared the antigen-specific
Ab responses in plasma to those in mucosal samples (Figure 2a
and b). Of all comparisons, systemic and mucosal gp41-specific
IgG most strongly correlated to one other (Figure 2a), in
contrast to gp41-specific IgA (Figure 2b) that correlated weakly
(R¼ 0.322, P¼ 0.040), suggesting that some IgA may be locally
produced in the mucosal compartment. We then examined IgG
vs. IgA in plasma and mucosal samples (Figure 2c and d) to
determine whether any correlations existed between IgG and
IgA levels in either compartment. Plasma HIV-1 gp41 Env IgG
and IgA correlated (R¼ 0.532, Po0.0001) (Figure 2c).
However, mucosal gp41 Env-specific IgG and IgA
responses correlate weakly (Figure 2d) (R¼ 0.366 and
R¼ 0.017). As noted by the circles, Ab concentrations in
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Figure 1 Frequent detection of anti-gp41 mucosal immunoglobulin (Ig)A, but infrequent detection of mucosal anti-gp120 IgA within 133 days
from enrollment. Frequency of HIV-specific antibodies in (a, b) plasma in 14–30 CHAVI 001 subjects and (c, d) mucosal sites in 13–23
CHAVI 001 subjects within 133 days of enrollment. IgG and IgA specific for the immunodominant epitope of gp41 were also tested in mucosal
samples from 12 individuals. nt, not tested.
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Table 1 Timing of systemic and mucosal gp41-specific IgA antibodies
gp41 Gag RT Nef gp120 P31
Fiebig stage No./totala % No./total % No./total % No./total % No./total % No./total %
(a) Plasma IgA
I/II 6/23 26.1 2/23 8.7 NT — NT — NT — NT —
III 7/14 50.0 3/14 21.4 NT — NT — NT — NT —
IV 15/17 88.2 10/17 58.8 3/7 42.9 3/7 42.9 2/8 25.0 0/7 0.0
V/VI 39/40 97.5 35/40 87.5 13/15 86.7 8/14 57.1 11/29 37.9 2/14 14.3
(b) Mucosal IgA
I/II 0/1 0 0/1 0 NT — NT — NT — NT —
III 0/2 0 0/2 0 NT — NT — NT — NT —
IV 7/21 33.3 4/8 50.0 0/7 0 0/7 0 1/7 14.3 0/7 0
V/VI 18/23 78.3 17/23 73.9 5/14 35.7 1/14 7.1 4/14 28.6 1/14 7.1
(c)
Antigen No. of subjectsb Median time to antibody response (range (days))c
gp41 14 13.5 (9–18)
p55 6 25.5 (14–40)
Abbreviations: Ig, immunoglobulin; NT, not tested.
(a) Frequency of HIV-1-specific plasma IgA responses per Fiebig25 stage in up to 30 CHAVI and 25 plasma donor patients is shown. Frequency was calculated by the number of
plasma samples positive per each Fiebig stage over the total number plasma samples measured in that stage. (b) Frequency of HIV-specific mucosal IgA responses were
measured in mucosal samples per Fiebig stage from up to 23 acute HIV-1 infection (AHI) patients. (c) Systemic HIV-1 gp41-specific IgA appears before anti-Gag IgA antibodies.
HIV-specific IgA responses were measured in 25 HIVþ seroconversion plasma donor panels by standard enzyme-linked immunosorbent assay and aligned to T0 (the time at
which viral load is first detectable), as previously described.
aNumber of subjects having an antigen-specific IgA positive sample in the designated Fiebig stage divided by the total number of subjects in that designated Fiebig stage.
bNumber of plasma donor subjects with positive IgA response.
cMedian time from T0 (the first day the viral load reaches 100 copies/ml).
Table 2 Peak concentration of HIV-1 gp41-specific antibodies in plasma and mucosal samples observed during Fiebig stage III
through V/VI of AHI
Plasma gp41-specific Ab (lg/ml) Mucosal gp41-specific Ab (lg/mg)
Number positive (n) Median (range) Mean±s.d. Number positive (n) Median (range) Mean±s.d.
IgG
All 23 546.3 (5.4–5194.8) 1242.4±1485.8 12 35.6 (2.4–444.9) 102.7±133.7
Male 16 1300.1 (5.4–5194.8) 1618.8±1632.8 9 32.5 (2.4–444.9) 111.2±151.8
Female 7 353.5 (128.8–1761.1) 555.4±554.8 3 72.1 (10.6–148.1 ) 76.0±68.9
IgA
All 23 12.5 (0.7–41.2) 12.5±9.4 12 4.4 (0.4–52.4) 9.2±14.2
Male 16 13.0 (0.7–41.2) 14.4± 10.3 9 9.0 (0.7–52.4) 11.6±15.7
Female 7 4.8 (1.2–13.0) 7.0±4.6 3 0.8 (0.4–3.2) 1.4±1.5
IgM
All 12 7.9 (0.3–26.7) 9.8±8.0 5 26,939 (15,110–112,989) 40,719±40,780
Male 10 6.7 (0.3–13.7) 6.9±4.2 5 26,939 (15,110–112,989) 40,719±40,780
Female 2 24.8 (22.9–26.7) 24.8±2.7 0 — —
Abbreviations: Ab, antibody; AHI, acute HIV-1 infection; Ig, immunoglobulin.
Peak plasma and mucosal HIV-1 gp41-specific antibody levels were determined in CHAVI 001 patients during the first 133 days post enrollment. Concentration is expressed in
mg/ml equivalents determined with a standard curve using 2F5 IgG, IgA, or IgM. Mucosal antibody levels are expressed as specific activity (mg of gp41-specific antibody/mg of
total antibody).
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line). These data indicate that some HIV-1-specific Ab
responses present at mucosal sites represent transudate.
However, the discordance between mucosal and systemic
HIV-specific Abs suggests that some fraction of the measured
HIV-1-specific mucosal response may be locally produced.
Thus, measurement of plasma HIV-1 Env IgA does not entirely
reflect the level or specificity of mucosal HIV-1 Env IgA.
Short half-life of the mucosal anti-gp41 Env IgA in AHI
To address the question of whether the initial mucosal Ab
response to HIV-1 infection is transient and therefore may have
been difficult to detect previously30, we examined 12 CHAVI
001 patients longitudinally (out to 133 days post enrollment)
(Figure 3) to determine the kinetics of the HIV-1-specific IgA
and IgG responses in both plasma (Figure 3a and c) and
mucosal compartments (Figure 3b and d). To normalize for
changes in total Ab concentrations, specific activity (HIV-1
gp41-specific Ab/total Ab) was determined for each mucosal
sample. Although mucosal HIV-1-specific IgA responses were
detected frequently in AHI, there was an early peak and
subsequent decline during the later phase of acute infection in
11 out of 12 patients (91.7%). This was in contrast to the
predominantly increasing or steady mucosal gp41 IgG
response. Likewise, of the 12 patients that we studied with
matching longitudinal plasma and mucosal samples, 10
(83.3%) of these patients had declining gp41-specific IgA in
the plasma (Figure 3e).
We applied an exponential decay model31 to determine the
Ab half-life of gp41-specific IgA in the plasma and mucosal
compartments during AHI among individuals with at least a
2-fold decrease in Ab response (Table 3). The model that fit best
for the mucosal samples assumes a lower asymptote greater
than zero (Ab responses plateaus at a non-zero level), whereas
the model for the plasma samples assumes that the lower
asymptote is zero (Ab response eventually declines all the way
to zero). Although the half-life of plasma gp41-specific IgA was
much longer (48.19 days (95% confidence interval
(CI)¼ 34.57–61.81)) than the half-life of mucosal IgA (2.71
days (95% CI¼ 2.06–3.36)), the fold decline (the delta from
peak to nadir) of HIV-1-specific IgA was similar in mucosal
(6.20-fold (95% CI¼  0.51, 12.92) and plasma (8.65-fold
(95% CI¼ 3.38–13.93) samples.
Confirmation of short half-life of anti-gp41 Env IgA in
plasma in additional AHI cohorts
To determine whether the overall systemic gp41-specific IgA
decline in the CHAVI 001 patients was common to other acute
infection cohorts, we examined additional patients for whom
we had longitudinal samples available for study in the CHAVI
001 cohort and, as well, compared Ab kinetics to that observed
in two other cohorts: the plasma donor cohort4 and Trinidad
cohort32,33. In sequential plasma samples from 44 patients, we
found that 28 patients demonstrated discordant gp41-specific




































































































Figure 2 Difference in systemic and mucosal immunoglobulin (Ig)A and IgG concentrations and specificities. Correlations of gp41 Env-specific
(a) IgG and (b) IgA in genital secretions vs. plasma during acute HIV-1 infection (AHI). Correlations of (c) plasma and (d) mucosal levels of HIV-1
Env-specific IgG vs. IgA during AHI. Specific activity in mucosal samples is calculated as mg of HIV-specific antibody (Ab) per mg total Ab.
Concentrations of anti-gp41 Ab calculated per 2F5 monoclonal Ab equivalents and concentrations of anti-gp120 Abs are calculated as the binding units
in the linear range multiplied by the dilution factor divided by total Ab concentration.
ARTICLES
696 VOLUME 6 NUMBER 4 | JULY 2013 |www.nature.com/mi
responses declined whereas gp41-specific IgG responses either
remained stable or increased over time. The kinetics of HIV-1-
specific IgG and IgA in the plasma donor cohort are shown in
Figure 4, where the HIV-1-specific IgG response appears at a
median time of 13 days post T0 (ref. 4) and continues to rise
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Figure 3 Rapid decline in mucosal HIV-specific immunoglobulin (Ig)A in acute HIV-1 infection subjects. HIV-1-specific IgG and IgA antibody
concentrations are shown for two representative subjects with (a, c) paired plasma and (b, d) genital fluid (seminal plasma and cervicovaginal lavage
(CVL). (a) Plasma and (b) mucosal HIV-specific IgM is shown for one subject. (e) Mucosal HIV gp41-specific IgA kinetics in 11 patients aligned to the peak
response.
Table 3 Half-life estimates for initial gp41 IgA decline in AHI
(exponential decay model) for individuals with at least a 2-fold
decrease in antibody response
HIV-1 gp41 IgA
Half-life (days) Fold decreasea
Estimate 95% CI Estimate 95% CI
Plasma (N¼ 10) 48.19 34.57, 61.81 8.65 3.38, 13.93
Mucosal (N¼ 11) 2.71 2.06, 3.36 6.20 0.51, 12.92
AHI, acute HIV-1 infection; CI, confidence interval; Ig, immunoglobulin.
The model that fit best for the mucosal samples assumes a lower asymptote greater
than zero (antibody response plateaus at a non-zero level), whereas the model for the
plasma samples assumes that the lower asymptote is zero (antibody response
eventually declines all the way to zero).
aAt lower asymptote for mucosal and 150 days post peak for plasma.
Table 4 Decline in systemic gp41-specific IgA in multiple
cohorts
No. of subjects
Cohort No. Samples per subjecta IgGþ /IgAþb IgAkc
Plasma donor 4–29 14 6
Trinidad 8–17 7 6
CHAVI 001 4–10 23 16
Total 44 28
Abbreviation: Ig, immunoglobulin.
aThe number of longitudinal samples per subject analyzed over the course of acute
infection are indicated.
bThe number of subjects with at least four time points that were tested that had
detectable anti-gp41 IgG and IgA to measure decline are indicated.
cNumber of subjects with increasing/stable IgG and Z2.5-fold decline in IgA from
peak level.
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that the HIV-1 gp41-specific IgA decline that we observed in
the CHAVI 001 cohort could be confirmed in additional AHI
cohorts.
Short half-life of IgA Abs in AHI is specific to HIV-1 IgA
The decline in gp41-specific IgA that we observed during AHI
suggested that HIV-1 does not stimulate long-lived HIV-1-
specific IgAþ B cells. To determine whether this was a
generalized downregulation of all IgA responses, we also
examined memory IgA responses specific to tetanus toxoid and
influenza antigens from vaccination (Figure 5a–c). Tetanus
toxoid and influenza IgA Ab responses could not be fit to the
exponential decay model and did not decline during AHI
during the time of gp41 IgA Ab decline. Moreover, the average
levels of total plasma IgA and IgG within this cohort did not
decline during acute infection. These data imply that the decline
in the IgA response is specific for HIV-1 and is not due
to a general downregulation of all memory IgA responses;
rather, the short half-life of HIV-1-specific IgA in AHI is more
likely due to Env stimulation of a short-lived B-cell response to
HIV-1.
Specific elevations in BAFF before initial HIV-1 Env Ab
To investigate potential mechanisms of HIV-1 antigen-specific
IgA decline, we measured the plasma and mucosal levels of two
cytokines, BAFF and APRIL (a proliferation inducing ligand),
known to regulate B-cell survival and activation. We first
measured longitudinal samples from seronegative donors and
found that BAFF levels typically remained stable under 1 ng/ml
over time (N¼ 7 donors, 10–12 time points each, from up to
60–120 days). We then examined plasma samples from acute
hepatitis B virus (HBV) (N¼ 10) and acute hepatitis C virus
(HCV) (N¼ 10) infection and found that levels of BAFF were
also stable during the acute phase of these infections, remaining
at levels similar to those found in uninfected patients whereas
viremia increased (Figure 6a). We then examined levels of
plasma BAFF in AHI (N¼ 20) and found that there was a peak
in the levels of BAFF, above 1 ng/ml, soon after HIV-1
transmission that preceded the peak in the HIV-1-specific Ab
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Figure 4 Initial decline in anti-gp41 immunoglobulin (Ig)A, but not anti-gp41 IgG during acute HIV-1 infection. Differential kinetics of systemic
HIV gp41-specific IgA and IgG antibodies following HIV-1 transmission in plasma donor subjects aligned by T0 (plasma viral RNA¼ 100 copies/ml)
in acute infection. OD, optical density.




















































































































Figure 5 Immunoglobulin (Ig)A decline is specific for HIV-1 infection.
During acute infection HIV-1 gp41-specific antibodies (a) decline over
time, in contrast to IgA antibodies specific for (b) tetanus toxoid and (c)
influenza (Fluzone). All antibody responses are plotted as a percentage of
levels measured at the peak of the gp41-specific IgA response.
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Acute HIV-1 cervicovaginal lavage  Acute HIV-1  seminal plasma
Figure 6 B-cell-activating factor (BAFF) is elevated before antibody production in acute HIV-1 infection, but is not elevated during acute hepatitis B virus (HBV) and
hepatitis C virus (HCV) infections. (a) Plasma panels from subjects with acute HBV infection (N¼ 10 donors, 10–12 time points each, up to 50 days)) and acute HCV
infection (N¼ 10 donors, 7–15 time points each, up to 50 days) were measured for levels of BAFF. Data from one representative subject infected with each virus are
shown.Sample timecoursesarealignedrelative to the timewhenvirus first reacheddetectable levels inplasma(200DNAcopies/ml forHBV(T200),600RNAcopies/ml
forHCV(T600)). (b)Anelevation inplasmaBAFFlevelsprecedes therise inanti-HIV immunoglobulin (Ig)Gand IgAantibody levelsduringacuteHIV-1 infection. (N¼21
donors, 8–22 time points each up to 40 days post T0 were tested for BAFF; antibody levels were also detected in 9 of these; data from two representative
subjects is shown). (c) Elevation in BAFF levels during the time of HIV-specific antibody elevations in mucosal samples. Longitudinal cervicovaginal lavage
samples (N¼ 5 patients) and seminal plasma (N¼ 4 patients) were tested (data from two representative individuals is shown). Correlation between plasma (d) BAFF
and(e)APRIL(aproliferation inducing ligand) levelswithviral load(VL).Data frompatient (outlier)arecircledandwhenthesepointsareremoved,R¼0.27,P¼ 0.0032.
OD, optical density.
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mucosal fluid near the time of the initial HIV-1-specific Ab
response (N¼ 5 cervicovaginal lavage and N¼ 4 longitudinal
seminal plasma samples) (Figure 6c). Levels of APRIL in these
same patients also showed an increase at similar times to that of
BAFF, although the levels of APRIL were generally higher
(peaking at 2–12 ng/ml). The transient upregulation of APRIL
during this period was specific to AHI, as there were not similar
elevations in APRIL in acute HBV and HCV plasma donor
panels at similar time points. To determine whether higher
transient levels of BAFF could be a consequence of higher T-cell
activation and IFNg production due to viral replication during
AHI, we examined whether plasma BAFF and APRIL cor-
related with viral load (Figure 6d and e). BAFF levels, but not
APRIL, were weakly correlated with viral load. HIV-1 gp41 Env
IgA Ab levels did not correlate with viral load (R¼  0.140,
P¼ 0.174). These data suggest that the levels of BAFF, APRIL
and HIV-1-specific IgA do not directly reflect increased virus
replication and immune activation in these patients.
DISCUSSION
In mucosal samples collected within weeks of HIV-1 transmis-
sion, we show that mucosal IgA HIV-1-specific Abs were
frequently detected (87%) in acute infection, albeit at relatively
low levels compared with anti-Env IgG. Similar to the initial
plasma IgG response to gp41,4 and the initial plasma B-cell
response to gp41 (ref. 34), we demonstrate here that the initial
mucosal Ab response is also directed to gp41 Env. The reason
for the focus of the initial Ab response to gp41, rather than to
gp120, is not fully understood. However, we have previously
reported34 that the initial gp41 IgG Ab response can be derived
from pre-existing cross-reactive memory B cells that are further
driven by HIV-1 infection. Previous reports indicated that there
was a paucity of HIV-1-specific IgA responses in HIV-1
infection;30 however, the HIV-1 antigens used and the later
timing during acute infection of the samples likely accounted
for the low detection of Ab responses in prior studies.
Moreover, previous studies have reported the detection of
high frequencies of HIV-1-specific IgA responses in seminal
plasma from chronically infected patients.35,36 In agreement
with this, we found that in the majority of patients, gp41-
specific IgA responses peaked and then declined in concentra-
tion in both the mucosal and systemic compartments during
AHI, whereas gp120 IgA appeared later. The ratio of HIV-1-
specific IgA: IgG was relatively low in genital fluids; although
there is a higher natural ratio of IgA: IgG in mucosal fluids
compared with plasma. The mechanism for the relatively low
HIV-1-specific IgA, compared with HIV-1-specific IgG, in
mucosal fluids during HIV-1 infection is not well understood.
The ratio could be reflective of contributions from plasma
transudate or a result of mechanisms that cause defects in
mucosal class switching, such as HIV-1 Nef-mediated inhibi-
tion of class switching to IgA37 or potentially destruction of
T-regulatory cells important in the development of IgAþ
mucosal B cells.38
A long-lived protective Ab response is highly desired for any
vaccine and has been particularly problematic for HIV-1
vaccines; thus, measuring the Ab half-life of HIV-1-specific
responses systemically and at mucosal sites is important for
understanding the mechanisms to induce long-lived effective
Ab responses. Here, we found that in acute infection, gp41 Env-
specific IgA responses had a very short half-life both
systemically and mucosally: B48 days in the blood and 2.7
days in the mucosal secretions during the acute phase of HIV-1
infection. The half-life of total IgA in the blood is B4–9 days,39
whereas the predominant IgG subclasses (IgG1, IgG2) have a
longer half-life (21 days)40 due to the ability of IgG Abs to bind
to FcRn, preventing lysosomal degradation.41
We previously demonstrated that in an HIV-1 vaccine trial
and anti-retroviral-treated chronic HIV-1 infection, the half-
life of IgG Env gp120 Abs is short compared with tetanus and
influenza Abs, is dependent on specific antigen drive, and has
the hallmark of being maintained by short-lived memory B cells
rather than long-lived plasma cells.42 This finding that gp41-
specific mucosal IgA responses have a remarkably shorter half-
life (2.7 days) than gp41-specific IgG is extraordinary and
suggests isotype-specific rapid catabolism of mucosal IgA. Also,
these data suggest that long-lived plasma cells secreting HIV-1-
specific IgA are not generated immediately following HIV-1
transmission. However, it is important to note that the HIV-1-
specific IgA response does not decline to negative. In chronic
HIV-1 infection, Env-specific IgA responses are present in both
plasma and at mucosal sites such as breastmilk;43 thus, likely
ongoing virus replication can stimulate HIV-1-specific IgA
responses. Further studies are needed to quantify and compare
the levels of HIV-1-specific secretory, monomeric, and dimeric
IgA in mucosal secretions throughout infection and in response
to HIV-1 vaccination.
T-cell-independent class switching can occur by activation of
B cells by BAFF and APRIL secretion from dendritic cells.44,45
We found that the cytokines BAFF and APRIL are elicited in
plasma and mucosal secretions just before the initial rise in the
HIV-1 Env-specific IgG and IgA responses during AHI. In
acute and recent HIV-1 infection, naive B cells were
significantly reduced relative to the total B-cell population
in both the blood and terminal ileum.15 Scholz et al.46
demonstrated that inhibition of BAFF can result in decreased
numbers of naive B cells and primary immune responses with
little effect on memory B cells and long-lived plasma cells. One
possibility for the short half-life of the anti-Env IgA response in
acute infection is that although innate immune stimulation can
release factors that promote B-cell class switching, this occurs
through a T-cell-independent pathway.47 A subsequent T-cell-
dependent pathway for HIV-1-specific Ab induction may be
hampered due to the massive CD4 T-cell depletion that occurs
early in infection.10,48,49 The transient peak in cytokines that
stimulate B-cell responses, and the short half-life of HIV-1 Env
IgA coupled with massive CD4 depletion and damage to
mucosal generative B-cell environments15 in AHI are con-
sistent with a T-independent pathway for the initial HIV-1 Ab
response.
We recently reported on the concentrations and kinetics
of the IgG3 subclass of the anti-HIV response during recent
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HIV-1 infection.31 Anti-gp41 IgG3 appears first among the
different antigen-specific IgG3 responses, and the anti-gp41,
anti-Gag and anti-RT IgG Abs decline with defined kinetics
within the first year of infection, which could be useful as part of
an algorithm for measuring HIV-1 incidence.31 The half-life
estimates and concentrations of anti-gp41 IgA Abs systemically
and in genital fluids during acute infection, as reported here, are
additional measurements that have potential as part of an HIV-
1 incidence algorithm. There is precedence for the utilization of
pathogen-specific IgA in tests for recent infection, such as in the
case of dengue,50 which utilizes the short half-life of IgA for
determining recent infection. Additional characterization of
HIV-1-specific IgA responses at later stages in HIV-1 infection
is needed to determine whether the IgA profile can distinguish
recent from chronic HIV-1 infection.
The protective properties (e.g., inhibition of
transport through mucus, Ab-dependent cellular cytotoxicity,
neutralization, phagocytosis) of mucosal IgA Abs with different
HIV-1 specificities have not been fully delineated.
However, some studies of persistently highly HIV-1 exposed
but uninfected individuals demonstrated that HIV-1-specific
mucosal Abs could be detected, and in some cases, neutralizing
IgA responses were found in both sera and mucosal fluids in the
absence of detectable HIV-1-specific IgA responses.51–54 In
addition to having antiviral properties, antigen-specific IgA
Abs may block some IgG functions.55,56 Recent results
from the RV144 trial57 raise the hypothesis that plasma
anti-gp120 IgA Abs with specific epitope specificities
may have potentially blocked anti-gp120 IgG Abs with
functional activity. However, it is unknown whether mucosal
IgA had a role in observed protection in RV144, as no mucosal
samples were collected. In a recent report of a heterologous
prime boost, rectal challenge study in non-human primates,
rectal anti-Env IgG was among a number of variables that
correlated with reduced acquisition risk.58 Moreover, IgA Abs
with specificity for gp41 Env have been reported to have
potentially protective functional properties;59–61 thus the
focused specificity of IgA Abs to gp41 during acute infection
suggests that these easy to elicit Abs at the mucosal surface
could potentially have some protective effect if present before
HIV-1 transmission and if a durable HIV-1 Env-specific B-cell
response can be elicited by HIV-1 vaccination. We previously
reported that the initial gp41-specific IgG Abs can capture
infectious virions;62 however, additional work is needed to fully
determine the spectrum of inhibitory capabilities of both
systemic and mucosal IgA and IgG Abs induced in acute
infection, including any potential effects of mucosal HIV-1 Abs
on transmission.
Finally, our data highlight the need to determine the
mechanisms that lead to the induction of long-lived
effective mucosal antibody responses. Whereas vaccination
for influenza63 and polio64 or infection with rotavirus65 can
elicit IgA responses that can be protective, as yet it
remains uncertain whether either infection or vaccination
with HIV-1 Env can generate protective mucosal or systemic
IgA responses.
METHODS
Participants and specimen collection. HIV-1-infected individuals
from three different acute infection cohorts were examined: 25 HIV-
1þ plasma donors (Clade B),20 8 AHI patients from the Trinidad
cohort (Clade B),66 and 30 AHI patients from the CHAVI 001 acute
infection cohort (Clades B and C from United States, South Africa, and
Malawi).4,62,67 HIV-1, HBV, and HCV acute infection plasma donor
samples and uninfected control plasma donor samples were purchased
from Zeptometrix (Franklin, MA).20 Paired blood and seminal plasma
or ectocervicovaginal lavage fluids were obtained from the CHAVI 001
acute infection cohort.4,62,67 Seminal plasma samples were obtained
from ejaculate collected directly into a refrigerated sterile cup con-
taining 2.5 ml of viral transport medium (Roswell Park Memorial
Institute medium, 1,000 U penicillin, 1 mg/ml streptomycin, 200 U/ml
nystatin). After liquefaction, the sample was transferred to a centrifuge
tube containing 2.5 ml of 2 protease inhibitor buffer and the total
volume and dilution factor were calculated. Semen was centrifuged at
800 g for 10 min (18–26 1C), and supernatant was aliquoted and stored
( 80 1C). Ectocervicovaginal lavage fluids (cervicovaginal lavage)
were obtained through repeated rinsing of the cervix and ectocervix
with 10 ml total of saline or buffered saline. Fluid was then transferred
to a sterile tube with 100 protease inhibitor and centrifuged at
600–800 g for 10 min (18–26 1C) to remove cells. The supernatant,
including any mucus, was aliquoted and stored at  80 1C. All work
performed as part of this study was reviewed and approved by the
institutional review boards of each participating center, Duke
University Medical Center, and the Division of AIDS, NIH.
Specimen preparation for IgG removal. For detection of IgA and IgM
Abs, IgG was removed using protein G columns, as previously
described.4,57
Binding Ab assay. Customized multiplex HIV-1-binding assays (Bio-
Plex instrument (Bio-Rad, Hercules, CA)) were performed as pre-
viously described4 to determine IgG, IgA, and IgM responses specific
for recombinant HIV-1 p55 or p24 Gag (BD Biosciences, San Jose,
CA), recombinant HIV-1 gp41 MN (Immunodiagnostics, Woburn,
MA), a previously described artificial multi-clade group M consensus
gp120 Env protein (Con6 gp120) (ref. 68), HIV-1 p66RT (Protein
Sciences, Meriden, CT), HIV-1 recombinant Nef (Genway, San Diego,
CA), recombinant HIV-1 Tat (Advanced Bioscience, Kensington,
MD), and recombinant HIV-1 p31 Integrase (Genway).4 To determine
concentration of Abs binding to the 2F5 epitope, 2F5 monoclonal Abs
(IgG, IgA, IgM) (Polymune Scientific, Vienna, Austria) were titrated
on gp41-coupled beads to generate a standard curve. In addition, the
following peptides (Primm Biotech, Cambridge, MA) were used: (gp41
immunodominant region, RVLAVERYLRDQQLLGIWGCSGKLI
CTTAVPWNASWSNKSLNKI), SP62 (gp41 MPER, QQEKNE-
QELLELDKWASLWN). Immunodominant and MPER tetramers
were utilized for the detection of epitope-specific responses.69 HIV-1-
binding Ab measurements and measurement of IgA Abs to tetanus
toxoid and influenza (Fluzone 2007, Sanofi Pasteur) by standard
enzyme-linked immunosorbent assay (ELISA) were performed as
previously described.42 Total IgG and IgA Ab measurements for
calculating specific activity were performed using Bio-Plex Pro human
isotyping 7-plex panel (Bio-Rad) according to the manufacturer’s
instructions. The positivity criteria per HIV-1 antigen per Ab isotype
was determined by screening Z30 seronegative patients. A stan-
dardized HIV-1positive (HIVþ ) control was titrated on each assay
(tracked with a Levy-Jennings plot with acceptance of titer only within
3 s.d’s of the mean). Standard curves generated using titrated
monoclonal Abs and concentrations were used to obtain a four-
parameter logistic equation to determine concentrations of Ab in
patient samples (SigmaPlot, Systat Software, Chicago, IL). The coef-
ficient of variation per sample was r15%. Two negative sera and two
HIV-1þ control sera were included in each assay to ensure specificity
and for maintaining consistency and reproducibility between assays.
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BAFF/APRIL ELISA. Concentrations of BAFF and APRIL in plasma
and mucosal fluids were measured in duplicate by colorimetric ELISA
per manufacturer’s instructions (Human BAFF Quantikine ELISA
from R&D Systems, Abingdon, UK, and Human APRIL Platinum
ELISA from eBioscience, Hatfield, UK).
Statistical analysis. Antibody half-life estimates were obtained with
an exponential decay model (as previously described),31 based on
aligning samples obtained on or after their observed peak plasma or
mucosal IgA Ab response. Briefly, estimates for the Ab half-lives were
determined by using the data at or post peak (the highest value) and
then computing the half-life by fitting an exponential decay model
from peak to the last time point. A single exponential decay model was
applied to the data for the mucosal Ab responses:
y¼ðb0 b1Þe xtb2 þ b1;
although a reduced exponential decay model was fit for the plasma
antigens:
y¼ b0e xtb2 ;
Where, b0 is the level at time zero, xt is time, b1 is the lower asymptote,
and b2 is the exponential rate of decay such that ln(2)/ b2 is the
computed half-life. A random subject effect was assumed. For group
comparisons between means, unpaired t tests were performed in
Graphpad Prism (La Jolla, CA). Spearman correlations between
groups were also performed in Graphpad Prism.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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